Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Dyne Therapeutics, Inc. - Common Stock (NQ:DYN)

21.66 +0.48 (+2.27%)
Streaming Delayed Price Updated: 1:55 PM EST, Nov 24, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,148,408
Open 21.30
Bid (Size) 21.62 (200)
Ask (Size) 21.69 (100)
Prev. Close 21.18
Today's Range 21.10 - 22.27
52wk Range 6.360 - 31.32
Shares Outstanding 58,310,703
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Why Dyne Therapeutics Stock Was Crushing it This Week ↗
The company has solid potential with its development of drugs targeting muscle disorders. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Jazz Pharmaceuticals, Sigma Lithium, Zymeworks And Other Big Stocks Moving Higher On Monday ↗
 
Via Benzinga

Performance

YTD
-14.9%
-14.9%
1 Month
+26.5%
+26.5%
3 Month
+66.6%
+66.6%
6 Month
+85.1%
+85.1%
1 Year
-26.5%
-26.5%

More News

Read More
News headline image
Dyne Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights
From Dyne Therapeutics, Inc.
Via GlobeNewswire
Dyne Therapeutics Stock Soars After Rival Avidity Biosciences Gets Acquired By Novartis ↗
Via Stocktwits
News headline image
Dyne Therapeutics to Present at Upcoming Investor Conferences
From Dyne Therapeutics, Inc.
Via GlobeNewswire
News headline image
Why Dyne Therapeutics Stock Crushed the Market on Monday ↗
Via The Motley Fool
News headline image
Which stocks are moving on Monday? ↗
Via Chartmill
News headline image
Keep an eye on the top gainers and losers in Monday's session. ↗
Via Chartmill
News headline image
12 Health Care Stocks Moving In Monday's Intraday Session ↗
Via Benzinga
News headline image
Janus Henderson, Avidity Biosciences, BridgeBio Pharma And Other Big Stocks Moving Higher On Monday ↗
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
Via Benzinga
News headline image
Why Avidity Biosciences Shares Are Trading Higher By Around 42%; Here Are 20 Stocks Moving Premarket ↗
Via Benzinga
News headline image
Dyne Therapeutics Announces Additional One-Year Clinical Data Demonstrating Functional Improvement from Phase 1/2 ACHIEVE Trial of Zeleciment Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 (DM1)
From Dyne Therapeutics, Inc.
Via GlobeNewswire
News headline image
Dyne Therapeutics Appoints Brian Posner to its Board of Directors
From Dyne Therapeutics, Inc.
Via GlobeNewswire
News headline image
Dyne Therapeutics Receives Orphan Drug Designation in Japan for DYNE-251 in Duchenne Muscular Dystrophy
From Dyne Therapeutics, Inc.
Via GlobeNewswire
News headline image
Dyne Therapeutics to Present at Upcoming Investor Conferences
From Dyne Therapeutics, Inc.
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc. - DYN
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc. - DYN
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc. - DYN
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates ClaimsOn Behalf of Investors of Dyne Therapeutics, Inc. - DYN
From Pomerantz LLP
Via GlobeNewswire
News headline image
Dyne Therapeutics Announces FDA Breakthrough Therapy Designation for DYNE-251 in Duchenne Muscular Dystrophy (DMD)
From Dyne Therapeutics, Inc.
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc. - DYN
From Pomerantz LLP
Via GlobeNewswire
News headline image
These Analysts Lower Their Forecasts On Dyne Therapeutics Following Q2 Loss ↗
Via Benzinga
News headline image
Dyne Reports Wider Loss in Fiscal Q2 ↗
Via The Motley Fool
News headline image
Dyne Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights
From Dyne Therapeutics, Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Dyne Therapeutics, Inc. - Common Stock publicly traded?
Yes, Dyne Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Dyne Therapeutics, Inc. - Common Stock trade on?
Dyne Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Dyne Therapeutics, Inc. - Common Stock?
The ticker symbol for Dyne Therapeutics, Inc. - Common Stock is DYN on the Nasdaq Stock Market
What is the current price of Dyne Therapeutics, Inc. - Common Stock?
The current price of Dyne Therapeutics, Inc. - Common Stock is 21.66
When was Dyne Therapeutics, Inc. - Common Stock last traded?
The last trade of Dyne Therapeutics, Inc. - Common Stock was at 11/24/25 01:55 PM ET
What is the market capitalization of Dyne Therapeutics, Inc. - Common Stock?
The market capitalization of Dyne Therapeutics, Inc. - Common Stock is 1.26B
How many shares of Dyne Therapeutics, Inc. - Common Stock are outstanding?
Dyne Therapeutics, Inc. - Common Stock has 1B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.